PMID: 6987993Mar 1, 1980Paper

The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia

Atherosclerosis
P Schwandt, P Weisweiler

Abstract

The effect of 3 months' treatment with D-thyroxine on the lipoprotein lipids and apolipoproteins AI and B was investigated in 12 patients with type IIa hyperlipoproteinemia. VLDL, LDL and HDL were separated by preparative ultracentrifugation. Both apolipoproteins were measured in serum by electroimmunoassay procedures with monospecific antisera. There was a significant decrease of cholesterol, phospholipids and apolipoprotein B in serum and of all lipids in the LDL class. VLDL and HDL lipids and apolipoprotein AI showed no significant alterations. The atherogenic ratios LDL/HDL lipids and apolipoprotein B/apolipoprotein AI were lowered with the most pronounced effect on the ratio between the two apoliopoproteins. It is concluded that there is an effective reduction of LDL particles by D-thyroxine. Further investigations are necessary to evaluate whether lipoprotein lipids or apolipoproteins are a better discriminator of the influence on atherosclerotic risk in type IIa hyperlipoproteinemia.

References

Jul 16, 1979·Clinica Chimica Acta; International Journal of Clinical Chemistry·P Schwandt, P Weisweiler
Jan 27, 1975·JAMA : the Journal of the American Medical Association

Citations

Jan 1, 1986·Journal of the American College of Nutrition·W A ForsytheJ J Anderson
Oct 11, 2011·Cardiology in Review·Irene A WeissWilliam H Frishman
Jan 15, 1982·Klinische Wochenschrift·J G WechslerH Ditschuneit
Jul 1, 1982·Klinische Wochenschrift·P Schwandt

Related Concepts

Apolipoproteins
Clinical Trials
Choloxin
Hyperlipoproteinemia Type IIa
Lipoproteins
Alpha-1 Lipoprotein
LDL-1
Lipoproteins, VLDL1

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.